-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.O2.6 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Targeted Therapies and Novel Therapies

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Non-Biological therapies, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Diseases, Therapies, Myeloid Malignancies
Monday, December 13, 2021: 2:45 PM-4:15 PM
Georgia Ballroom 1-3 (Georgia World Congress Center)
Moderators:
Verena I Gaidzik, MD, University Hospital of Ulm and Lorenzo Brunetti, MD, PhD, University of Perugia
Disclosures:
No relevant conflicts of interest to declare.
2:45 PM

Pau Montesinos, PhD, MD1*, Christian Recher, MD2, Susana Vives, MD3*, Ewa Zarzycka, MD4*, Jianxiang Wang, MD5, Giambattista Bertani, MD6*, Michael Heuser, MD7, Rodrigo T. Calado, MD, PhD8, Andre C. Schuh, MD9, Su-Peng Yeh, MD10*, Scott R. Daigle, MS11*, Jianan Hui, PhD11*, Vickie Zhang, PhD11*, Shuchi S. Pandya, MD11*, Diego A. Gianolio, PhD11*, Stephane de Botton, MD, PhD12* and Hartmut Döhner, MD13

1Hospital Universitari i Politècnic La Fe, Valencia, Spain
2Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse, Toulouse, France
3Hospital Universitario Germans Trias i Pujol-ICO Badalona, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain
4Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland
5Institute of Hematology & Hospital of Blood Disease – Peking Union Medical College, Beijing, China
6ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
7Hannover Medical School, Hannover, Germany
8Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil
9Princess Margaret Cancer Centre, Toronto, ON, Canada
10China Medical University, Taichung, Taiwan
11Servier Pharmaceuticals, Boston, MA
12Institut Gustave Roussy, Villejuif, France
13Ulm University Hospital, Ulm, Germany

3:00 PM

Jorge E. Cortes, MD1, Jordi Esteve, MD, PhD2, Ashish Bajel, MBBS, FRACP, FRCPA3, Karen Yee, MD4, Thorsten Braun, MD, PhD5, Stephane De Botton6*, Pierre Peterlin7*, Christian Recher, MD8, Xavier Thomas, MD, PhD9, Justin Watts, MD10, Montserrat Arnan Sangerman, MD PhD11*, Antonio Curti, MD, PhD12, Carolyn Grove, MBBS, PhD13*, Brian A. Jonas, MD, PhD, FACP14, Francesco Lanza, MD15*, Olivier Legrand, MD, PhD16*, Pau Montesinos, PhD, MD17*, Prapti Patel, MD18, Thomas Prebet, MD, PhD19, Eunice S. Wang, MD20, Olga Polyanskaya, MS21*, Julie Brevard, MPH21*, Jennifer Sweeney21*, Pierre Fenaux, MD, PhD22 and Andrew H. Wei, MBBS, PhD23

1Georgia Cancer Center, Augusta, GA
2Hematology Department, Hospital Clinic de Barcelona, Barcelona, Spain
3Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia
4Princess Margaret Cancer Centre, Toronto, ON, Canada
5Hopital Avicenne, AP-HP, Paris XIII University, Bobigny, France
6Department of Haematology, Institut Gustave Roussy, Villejuif, France
7CHU de Nantes, Service d’hématologie Clinique, Nantes, France
8Institut Universitaire du Cancer Toulouse – Oncopole, Cedex, France
9Hematology Department, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Benite, France
10Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
11Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, Barcelona, Spain
12IRCCS Azienda ospedaliero-universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
13Department of Haematology, PathWest & Sir Charles Gairdner Hospital, Department of Health, Nedlands, WA, Australia
14Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, Sacramento, CA
15Hematology Institute, Ravenna, Italy
16Hematology Department, Saint-Antoine University Hospital, Paris, France
17Hematology Department, Hospital Universitario i Politecnico La Fe Valencia, Valencia, Spain
18Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX
19Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
20Roswell Park Comprehensive Cancer Center, Buffalo, NY
21Forma Therapeutics, Inc., Watertown, MA
22Department of Haematology, Saint-Louis Hospital, Paris, France
23Department of Haematology, The Alfred Hospital, Melbourne, VIC, Australia

3:15 PM

Eytan M. Stein, MD1, Ibrahim Aldoss, MD2, John F. DiPersio, MD, PhD3, Richard M. Stone, MD4, Martha L. Arellano, MD5, Galit Rosen, MD6, Michael L. Meyers, MD, PhD6*, Yifan Huang, PhD6*, Steve Smith6*, Rebecca G. Bagley, BA6*, Michael Thirman, MD7, Manish R. Patel, MD8 and Ghayas C. Issa, MD9

1Memorial Sloan Kettering Cancer Center, New York, NY
2City of Hope Comprehensive Cancer Center, Duarte
3Washington University School of Medicine – Siteman Cancer Center, St. Louis
4Dana-Farber Cancer Institute, Boston, MA
5Emory Winship Cancer Institute, Atlanta
6Syndax Pharmaceuticals, Inc, Waltham
7The University of Chicago, Chicago
8Florida Cancer Specialists – South, Sarasota
9Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 PM

Eunice S. Wang, MD1, Pau Montesinos, PhD, MD2*, Mark D. Minden, MD, PhD3, Je-Hwan Lee, MD, PhD4, Michael Heuser, MD5, Tomoki Naoe6*, Wen-Chien Chou, MD, PhD7, Kamel Laribi, MD8*, Jordi Esteve, MD, PhD9, Jessica K. Altman, MD10, Violaine Havelange, MD11*, Anne-Marie Watson12*, Elzbieta Patkowska, MD, PhD13*, Shufang Liu, PhD14*, Ruishan Wu, MS14*, Nisha Philipose, BPharm, MS14*, Jason E. Hill, PhD14*, Stanley Gill, PhD15*, Elizabeth Shima Rich, MD, PhD14 and Ramon V. Tiu, MD14

1Roswell Park Comprehensive Cancer Center, BUFFALO, NY
2Instituto de Investigación Sanitaria La Fe (IISLAFE), Hospital Universitari i Politècnic La Fe, Valencia, Spain
3Princess Margaret Hospital, Toronto, Canada
4Asan Medical Center, Seoul, Korea, Republic of (South)
5Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
6National Hospital Organization Nagoya Medical Center, Nagoya, Japan
7National Taiwan University Hospital, Taipei, Taiwan
8Department of Hematology, CH Le Mans, Le Mans, France
9Hematology Department, Hospital Clinic de Barcelona, Barcelona, Spain
10Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
11Cliniques Universitaires Saint-Luc, Brussels, Belgium
12Liverpool Hospital, Liverpool, NSW, Australia
13Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
14Astellas Pharma, Inc., Northbrook, IL
15Astellas Pharma Global Development, Northbrook, IL

3:45 PM

Curtis Lachowiez, MD1, Courtney D. DiNardo, MD, MSCE2, Koichi Takahashi, MD, PhD3, Sanam Loghavi, MD4, Lian-Chun Xiao5*, Tapan M. Kadia, MD6, Naval Daver, MD3, Maria Adeoti, R.N.3*, Nicholas Short, MD7, Koji Sasaki, MD8, Sa A Wang, MD9*, Gautam Borthakur, MD3, Ghayas C. Issa, MD3, Abhishek Maiti, MBBS2, Yesid Alvarado, MD2, Naveen Pemmaraju, MD3, Guillermo Montalban-Bravo, MD2, Lucia Masarova, MD2*, Musa Yilmaz, MD3, Nitin Jain, MD8, Michael Andreeff, MD, PhD3, Guillermo Garcia-Manero, MD3, Steven Kornblau, MD3, Farhad Ravandi, MB Bs3, Elias Joseph Jabbour, MD3, Marina Konopleva, MD, PhD2 and Hagop Kantarjian, MD2

1Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston
6Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
8Department of Leukemia, MD Anderson Cancer Center, Houston, TX
9Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

4:00 PM

Naval Daver, MD1, Kyoo Hyung Lee, MD, PhD2*, Chul Won Jung, MD, PhD3*, Sung-Soo Yoon, MD4, Martha L. Arellano, MD5, Jiyeon Yoon, PhD6*, Nora Lee, PHD6*, Hyunjin Kim, PhD6*, Jaeyeon Lee6*, Brian A. Jonas, MD, PhD, FACP7 and Seungjae Baek, MD, PhD6*

1MD Anderson Cancer Center, Houston, TX
2Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
3Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
4Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
5Emory University School of Medicine, Atlanta, GA
6Hanmi Pharmaceutical Co., Ltd., Seoul, Korea, Republic of (South)
7Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, Sacramento, CA

*signifies non-member of ASH